0.26
-0.0085(-3.13%)
Currency In USD
Address
450 East Jamie Court
South San Francisco, CA 94080
United States of America
Phone
650 392 0420
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
June 05, 2020
| Name | Title | Pay | Year Born |
| Mr. Graham K. Cooper | Executive Chairman | 55,000 | 1970 |
| Mr. Brandon Hants | Chief Financial Officer | 469,669 | 1977 |
| Dr. Randall Mrsny Ph.D. | Co-Founder & Director | 613,296 | 1955 |
| Dr. Bittoo Kanwar M.D. | Chief Medical Officer | 625,500 | 1976 |
| Dr. Tahir Mahmood Ph.D. | Co-Founder & Director | 870,290 | 1975 |
| Dr. Andy Whitney Ph.D. | Senior Vice President of Research & Translational Science | 0 | 1961 |
| Mr. Douglas A. Rich M.B.A, M.B.A. | Chief Technical Officer | 0 | 1969 |
| Mr. Derek Maclean Ph.D. | Senior Vice President of Pharmaceutical Sciences | 0 | N/A |
| Mr. Andrew H. Chang | Head of Investor Relations & Corporate Communications | 0 | N/A |
| Mr. Earl M. Douglas | Executive Vice President & Gen. Counsel | 0 | 1963 |
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.